US Patent Issued to IMPACT THERAPEUTICS (SHANGHAI) on Nov. 25 for "Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Nov. 25 -- United States Patent no. 12,479,848, issued on Nov. 25, was assigned to IMPACT THERAPEUTICS (SHANGHAI) INC (Shanghai).

"Substituted fused heteroaromatic bicyclic compounds as kinase inhibitors and the use thereof" was invented by Sui Xiong Cai (Shanghai), Ye Edward Tian (Shanghai) and Xiaozhu Wang (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The disclosure provides novel substituted fused heteroaromatic compounds as represented in Formula I, wherein A1-A6 and R1-R4 are defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inhibitors. Therefore, the compounds of the disclosure may be used to treat ATR-mediated diseases, disorders ...